Prakash Deedwania

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome
    Prakash C Deedwania
    VA Central California Health Care System and University of California San Francisco, Fresno, California, USA
    Am J Cardiol 95:360-6. 2005
  2. pmc Benefits of statin therapy and compliance in high risk cardiovascular patients
    Joel A Lardizabal
    Division of Cardiology, Department of Medicine, University of California in San Francisco Fresno MEP, Fresno, CA, USA
    Vasc Health Risk Manag 6:843-53. 2010
  3. doi request reprint Statins in chronic kidney disease: cardiovascular risk and kidney function
    Prakash C Deedwania
    University of California, San Francisco School of Medicine, Fresno, CA
    Postgrad Med 126:29-36. 2014
  4. doi request reprint Does response of RAS blockade on serum K+ levels influence its glycemic-mitigating response when combined with hydrochlorothiazide?
    Prakash C Deedwania
    Cardiology Division, University of California at San Francisco School of Medicine, San Francisco, CA, USA
    J Clin Hypertens (Greenwich) 14:415-21. 2012
  5. pmc The anti-ischemic and anti-anginal properties of statins
    Joel A Lardizabal
    Division of Cardiology, Fresno Medical Education Program, University of California San Francisco, 155 N Fresno St, Fresno, CA 93301, USA
    Curr Atheroscler Rep 13:43-50. 2011
  6. ncbi request reprint Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study
    Prakash Deedwania
    Veterans Affairs Central California Healthcare System and University of California San Francisco School of Medicine, San Francisco, CA, USA
    Lancet 368:919-28. 2006
  7. doi request reprint Atrial fibrillation in heart failure: a comprehensive review
    Prakash C Deedwania
    Department of Medicine, University of California, San Francisco, USA
    Am J Med 123:198-204. 2010
  8. ncbi request reprint Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II)
    Prakash C Deedwania
    University of California San Francisco, School of Medicine, Fresno, CA 93703, USA
    J Cardiometab Syndr 1:295-300. 2006
  9. ncbi request reprint Diabetes and vascular disease
    Prakash Deedwania
    Department of Medicine, VACCHCS UMC, UCSF Program at Fresno, 2615 E Clinton Ave, Fresno, CA 93703, USA
    Expert Rev Cardiovasc Ther 6:127-38. 2008
  10. ncbi request reprint Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE)
    Prakash Deedwania
    UCSF School of Medicine, San Francisco, Calif, USA
    Circulation 115:700-7. 2007

Detail Information

Publications58

  1. ncbi request reprint Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome
    Prakash C Deedwania
    VA Central California Health Care System and University of California San Francisco, Fresno, California, USA
    Am J Cardiol 95:360-6. 2005
    ..Rosuvastatin had the most favorable effect on the atherogenic lipid profile of MS overall...
  2. pmc Benefits of statin therapy and compliance in high risk cardiovascular patients
    Joel A Lardizabal
    Division of Cardiology, Department of Medicine, University of California in San Francisco Fresno MEP, Fresno, CA, USA
    Vasc Health Risk Manag 6:843-53. 2010
    ..To fully reap the benefits of statin therapy, interventions which improve long-term treatment compliance in real-world settings should be encouraged...
  3. doi request reprint Statins in chronic kidney disease: cardiovascular risk and kidney function
    Prakash C Deedwania
    University of California, San Francisco School of Medicine, Fresno, CA
    Postgrad Med 126:29-36. 2014
    ..This review examines improved cardiovascular outcomes with statin treatment in patients with CKD (excluding end-stage renal disease) and investigates the effects of statin therapy on kidney function. ..
  4. doi request reprint Does response of RAS blockade on serum K+ levels influence its glycemic-mitigating response when combined with hydrochlorothiazide?
    Prakash C Deedwania
    Cardiology Division, University of California at San Francisco School of Medicine, San Francisco, CA, USA
    J Clin Hypertens (Greenwich) 14:415-21. 2012
    ..Thus, the metabolic response to hydrochlorothiazide was improved with addition of valsartan through an enhanced insulin response that was not greatly affected by changes in potassium levels...
  5. pmc The anti-ischemic and anti-anginal properties of statins
    Joel A Lardizabal
    Division of Cardiology, Fresno Medical Education Program, University of California San Francisco, 155 N Fresno St, Fresno, CA 93301, USA
    Curr Atheroscler Rep 13:43-50. 2011
    ..The anti-ischemic effects of statins further strengthen their role as a crucial component of the optimal medical therapy for CHD...
  6. ncbi request reprint Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study
    Prakash Deedwania
    Veterans Affairs Central California Healthcare System and University of California San Francisco School of Medicine, San Francisco, CA, USA
    Lancet 368:919-28. 2006
    ....
  7. doi request reprint Atrial fibrillation in heart failure: a comprehensive review
    Prakash C Deedwania
    Department of Medicine, University of California, San Francisco, USA
    Am J Med 123:198-204. 2010
    ..The role of non-anti-arrhythmic therapeutic agents also is being explored. Further progress toward improved understanding the complex relationship between atrial fibrillation and heart failure should improve management strategies...
  8. ncbi request reprint Application of recent definitions of the metabolic syndrome to survey data from the National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE II)
    Prakash C Deedwania
    University of California San Francisco, School of Medicine, Fresno, CA 93703, USA
    J Cardiometab Syndr 1:295-300. 2006
    ..The metabolic syndrome is common in patients receiving lipid-lowering therapy in an office-based setting. Three recent definitions resulted in similar estimates of its prevalence...
  9. ncbi request reprint Diabetes and vascular disease
    Prakash Deedwania
    Department of Medicine, VACCHCS UMC, UCSF Program at Fresno, 2615 E Clinton Ave, Fresno, CA 93703, USA
    Expert Rev Cardiovasc Ther 6:127-38. 2008
    ..The components of comprehensive risk reduction strategy consist of lifestyle changes, glycemic control, control of dyslipidemia and hypertension...
  10. ncbi request reprint Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE)
    Prakash Deedwania
    UCSF School of Medicine, San Francisco, Calif, USA
    Circulation 115:700-7. 2007
    ..However, no studies to date have assessed intensive versus moderate statin therapy in older patients with stable coronary syndromes...
  11. doi request reprint Low high-density lipoprotein cholesterol and increased cardiovascular disease risk: an analysis of statin clinical trials
    Prakash Deedwania
    Veterans Affairs Central California Health Care System University of California San Francisco, 2615 East Clinton Avenue, Fresno, California 93703, USA
    Am J Cardiol 104:3E-9E. 2009
    ..This article presents an overview of statin clinical trials and discusses implications for the clinical management of patients with low HDL cholesterol levels and increased cardiovascular risk...
  12. ncbi request reprint Hypertension as a cardiometabolic risk
    Sundararajan Srikanth
    Department of Medicine, UCSF School of Medicine, San Francisco, Fresno, CA, USA
    Indian Heart J 62:394-401. 2010
    ..Thus, when evaluating an individual with high blood pressure, the presence of other cardiometabolic risk factors should be sought and treated appropriately...
  13. doi request reprint Primary and secondary prevention strategy for cardiovascular disease in diabetes mellitus
    Sundararajan Srikanth
    Division of Cardiology, VACCHCS CMC, UCSF Program at Fresno, Fresno, CA, USA
    Cardiol Clin 29:47-70. 2011
    ..Prevention of diabetes and delaying its onset should also be an important aspect in future health care strategy and research to confront the oncoming tsunami of CVD related to diabetes...
  14. ncbi request reprint Bedside evaluation of cardiac markers. Point-of-care testing can differentiate acute coronary syndromes
    Ezra A Amsterdam
    University of California, Davis, School of Medicine, USA
    Postgrad Med 118:15-6, 19-22. 2005
    ..The authors also explore the potential of point-of-care testing for cardiac injury markers in the timely and accurate identification of ACS...
  15. ncbi request reprint Evolving treatment options for prevention of cardiovascular events in high-risk hypertensive patients
    Prakash Deedwania
    Cardiology Division, VACCHS University of California, San Francisco, Fresno, CA 93703, USA
    J Clin Hypertens (Greenwich) 9:883-8. 2007
    ..The Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET) is evaluating the cardioprotective effect of an ACE inhibitor (ramipril) plus an ARB (telmisartan) in high-risk patients...
  16. doi request reprint Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating β-blockers
    Prakash Deedwania
    Division of Cardiology, VACCHCS UCSF School of Medicine, University of California at San Francisco, Fresno, CA 93703, USA
    J Clin Hypertens (Greenwich) 13:52-9. 2011
    ..Because of these effects, vasodilating β-blockers may represent a favorable option in the treatment of high-risk patients with hypertension...
  17. ncbi request reprint Coronary artery disease in South Asians: evolving strategies for treatment and prevention
    Prakash Deedwania
    UCSF School of Medicine, San Francisco 93703, USA
    Indian Heart J 57:617-31. 2005
  18. ncbi request reprint Medical treatment of hypertension in patients with heart failure with preserved ejection fraction
    Richard G Kiel
    Veterans Affairs Central California Health Care System, UCSF Fresno Medical Education Program, 2615 E Clinton Ave, Fresno, CA, 93703, USA
    Curr Cardiol Rep 15:428. 2013
    ..As a result, when choosing an antihypertensive medication to treat or prevent HFPEF, it is important to tailor the choice of antihypertensive medication to an individual patient's specific symptoms and comorbidities. ..
  19. doi request reprint Effects of add-on nebivolol on blood pressure and glucose parameters in hypertensive patients with prediabetes
    Prakash Deedwania
    Department of Medicine, UCSF School of Medicine, University of California San Francisco, CA, USA
    J Clin Hypertens (Greenwich) 15:270-8. 2013
    ..3%, 6.6%, and 2.0%, respectively. Nebivolol, added to an ACE inhibitor or ARB, provides additional blood pressure reduction with little or no effect on glucose metabolism in hypertensive patients with prediabetes...
  20. doi request reprint Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease
    Joel A Lardizabal
    Division of Cardiology, Department of Medicine, University of California San Francisco Fresno Medical Education Program, Fresno, CA 93701, USA
    Cardiol Clin 29:87-103. 2011
    ..The strategy of using high-intensity statin therapy as the initial treatment approach in high-risk individuals, rather than focusing on specific cholesterol levels alone, remains a subject of debate...
  21. ncbi request reprint Management of coronary artery disease in patients with type 2 diabetes mellitus
    Sundararajan Srikanth
    Veterans Affairs Central California Health Care System University of California San Francisco Program at Fresno, 2615 East Clinton Avenue, Fresno, CA 93703, USA
    Curr Cardiol Rep 9:264-71. 2007
    ..We also identify controversies and issues that currently remain unresolved...
  22. ncbi request reprint An update on antithrombotic therapy in atrial fibrillation: the role of newer and emergent drugs
    Prakash Deedwania
    Division of Cardiology, Veterans Administration Central California Healthcare System University of California, San Francisco, Fresno, CA, USA
    Rev Cardiovasc Med 13:e89-104. 2012
    ..Other newer anticoagulant agents also provide us with possible suitable alternatives to warfarin, and their clinical use will depend on the results from ongoing studies...
  23. ncbi request reprint Endothelium-dependent vasodilation is impaired in healthy offspring of hypertensive parents
    Anil Bharani
    Division of Cardiology, Department of Medicine, MGM Medical College and Maharaja Yeshwant Rao Hospital, Indore, Madhya Pradesh, India
    Indian Heart J 63:255-8. 2011
    ..The study was designed to determine whether impaired endothelium-dependent vasodilation is present in Indian normotensive offspring with hypertensive parents...
  24. doi request reprint The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism
    Prakash Deedwania
    Cardiology Division, VACCHCS UCSF School of Medicine, Fresno, San Francisco, California 93703, United States
    Int J Cardiol 131:305-12. 2009
    ..Additional long-term controlled studies with appropriate follow-up are warranted to confirm the clinical potential of this drug, particularly its effects on dyslipidemia and other cardiovascular endpoints...
  25. ncbi request reprint Dyslipidemia in special populations: Asian Indians, African Americans, and Hispanics
    Vibhuti Singh
    Cardiology Division, VACCHCS UCSF, Fresno, CA 93703, USA
    Curr Atheroscler Rep 8:32-40. 2006
    ..Preliminary data suggest the need for stricter goals and increasingly aggressive therapy for these special populations, including administrative and educational interventions...
  26. ncbi request reprint Avoid the rush to judgment in acute coronary syndromes
    Prakash Deedwania
    University of California, San Francisco, School of Medicine, USA
    Postgrad Med 118:11-4, 22. 2005
  27. pmc Prediabetes is not an independent risk factor for incident heart failure, other cardiovascular events or mortality in older adults: findings from a population-based cohort study
    Prakash Deedwania
    University of California, San Francisco, CA, USA
    Int J Cardiol 168:3616-22. 2013
    ..Whether prediabetes is an independent risk factor for incident heart failure (HF) in non-diabetic older adults remains unclear...
  28. ncbi request reprint Dyslipidemia and lipid-lowering therapy in the elderly
    Prakash Deedwania
    VACCHCS UCSF Cardiology division, 2615 E Clinton Avenue, Fresno, CA 93703, USA
    Expert Rev Cardiovasc Ther 3:453-63. 2005
    ..With increasing life expectancy, it is critical for physicians to recognize the importance of detection and treatment of dyslipidemia in the elderly...
  29. ncbi request reprint Comprehensive risk reduction of cardiovascular risk factors in the diabetic patient: an integrated approach
    Sundararajan Srikanth
    Department of Medicine, VA Central California Health Care System University Medical Center, University of California, San Francisco Program at Fresno, 2615 East Clinton Avenue, Fresno, CA 93703, USA
    Cardiol Clin 23:193-210. 2005
    ....
  30. ncbi request reprint Mechanisms of endothelial dysfunction in the metabolic syndrome
    Prakash C Deedwania
    Division of Cardiology, Department of Medicine, VA Central California Health Care System and University of California at San Francisco Program, 2615 East Clinton Avenue 111, Fresno, CA 93703, USA
    Curr Diab Rep 3:289-92. 2003
    ....
  31. ncbi request reprint Metabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease?
    Prakash C Deedwania
    Division of Cardiology, Department of Medicine, VA Central California Health Care System and University of California San Francisco Program, Fresno, CA 93703, USA
    Circulation 109:2-4. 2004
  32. ncbi request reprint The benefits of intensive lipid lowering in patients with stable coronary heart disease with normal or high systolic blood pressure: an analysis of the Treating to New Targets (TNT) study
    John B Kostis
    University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903 0019, USA
    J Clin Hypertens (Greenwich) 10:367-76. 2008
    ..The effect of lower SBP on stroke was most pronounced in the lowest LDL-C tertile...
  33. ncbi request reprint ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients
    Raymond J Gibbons
    Circulation 107:149-58. 2003
  34. ncbi request reprint Diabetes and vascular disease: common links in the emerging epidemic of coronary artery disease
    Prakash C Deedwania
    Division of Cardiology, Department of Medicine, VA Central California Health Care System and UCSF Program, Fresno, and UCSF School of Medicine, San Francisco, California 93703, USA
    Am J Cardiol 91:68-71. 2003
  35. ncbi request reprint Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS)
    Mazen S Matalka
    Department of Pharmacy, Veterans Administration Central California Health Care System, Fresno, Calif 93703, USA
    Am Heart J 144:674-7. 2002
    ....
  36. ncbi request reprint Treating hypertension in patients with diabetes
    Helen Q Reynolds
    Ambulatory Care, Veterans Affairs Central California Health Care System, Fresno, USA
    Nurse Pract 27:11-21; quiz 21-3. 2002
    ..This article details evidence for blood pressure targets and antihypertensive drug choice in hypertensive patients with diabetes...
  37. ncbi request reprint The changing face of hypertension: is systolic blood pressure the final answer?
    Prakash C Deedwania
    Arch Intern Med 162:506-8. 2002
  38. ncbi request reprint The renin angiotensin system as a therapeutic target to prevent diabetes and its complications
    Kris Vijayaraghavan
    Research and Heart Failure Program, Scottsdale Cardiovascular Research Institute, Scottsdale, AZ 85251, USA
    Cardiol Clin 23:165-83. 2005
    ..In addition to lifestyle modifications, managing endothelial dysfunction and protecting the vasculature will help prevent diabetes and cardiovascular disease...
  39. ncbi request reprint 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to devel
    Theodore D Fraker
    J Am Coll Cardiol 50:2264-74. 2007
  40. ncbi request reprint 2007 chronic angina focused update of the ACC/AHA 2002 Guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to devel
    Theodore D Fraker
    Circulation 116:2762-72. 2007
  41. ncbi request reprint Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF
    Prakash C Deedwania
    Department of Veterans Affairs Medical Center, Fresno, Calif, USA
    Am Heart J 149:159-67. 2005
    ....
  42. ncbi request reprint Diabetes and hypertension, the deadly duet: importance, therapeutic strategy, and selection of drug therapy
    Prakash C Deedwania
    Department of Medicine, VA Central California Health Care System University Medical Center, University of California, San Francisco Program at Fresno, 2615 East Clinton Avenue 111, Fresno, CA 93703, USA
    Cardiol Clin 23:139-52. 2005
    ..Large outcome studies that compare different combination therapies in hypertensive,diabetic patients are needed...
  43. ncbi request reprint Diabetes is a vascular disease: the role of endothelial dysfunction in pathophysiology of cardiovascular disease in diabetes
    Prakash C Deedwania
    Division of Cardiology, Department of Medicine, VA Central California Health Care Systemn, University of California San Francisco Program, Fresno 93703, USA
    Cardiol Clin 22:505-9, v. 2004
    ..In this article the role of insulin, glucose,dyslipidemia, oxidative stress and various cellular mechanisms related to endothelial dys-function in diabetes are discussed in detail...
  44. ncbi request reprint Diabetes, prediabetes, and cardiovascular risk: shifting the paradigm
    Prakash C Deedwania
    Division of Cardiology, Department of Medicine, Veterans Affairs Central California Health Care System, University of California San Francisco Medical Education Program, Fresno, 93703, USA
    Am J Med 118:939-47. 2005
    ..Three clinical trials are being conducted to test whether early pharmacotherapy can reduce or delay the incidence of diabetes, and their results may well begin to shift the treatment paradigm toward earlier intervention...
  45. ncbi request reprint Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications
    George A Mensah
    National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Mailstop K 47, 4770 Buford Highway, NE, Atlanta, GA 30341, USA
    Cardiol Clin 22:485-504. 2004
    ..The prevention and control of overweight, obesity, metabolic syndrome, and diabetes pose special challenges for clinical and public heath practice as well as for basic, clinical, and population science research...
  46. ncbi request reprint Effect of aggressive versus moderate lipid-lowering therapy on myocardial ischemia: the rationale, design, and baseline characteristics of the Study Assessing Goals in the Elderly (SAGE)
    Prakash C Deedwania
    UCSF School of Medicine, USA
    Am Heart J 148:1053-9. 2004
    ..Older patients are at a particularly high risk. Few trials have specifically investigated the effects of lipid-lowering therapy with statins in older patients...
  47. ncbi request reprint Prevalence of metabolic syndrome in an Indian urban population
    Rajeev Gupta
    Department of Medicine, Monilek Hospital and Research Centre, Jawahar Nagar, Jaipur 302004, India
    Int J Cardiol 97:257-61. 2004
    ..To determine prevalence of the metabolic syndrome using United States Adult Treatment Panel-3 (ATP-3) guidelines in an urban Indian population...
  48. ncbi request reprint Angiotensin receptor blockers: Cardiovascular protection in the metabolic syndrome
    Prakash C Deedwania
    University of California at San Francisco, CA, USA
    J Renin Angiotensin Aldosterone Syst 7:S12-8. 2006
    ....
  49. ncbi request reprint Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease
    James Shepherd
    University of Glasgow, United Kingdom
    Mayo Clin Proc 83:870-9. 2008
    ....
  50. ncbi request reprint Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations
    Michael H Davidson
    Radiant Development, Chicago, Illinois, USA
    Am J Cardiol 96:556-63. 2005
    ..Most of those (75%) with cardiovascular disease in NEPTUNE II would be considered very high risk and candidates for aggressive therapy to reach the new optional treatment goals...
  51. ncbi request reprint Effects of lipid-altering treatment in diabetes mellitus and the metabolic syndrome
    Prakash C Deedwania
    formerly with the Heart Disease Prevention Clinic, University of Minnesota, Minneapolis, Minnesota, USA
    Am J Cardiol 93:18C-26C. 2004
    ..Prospective data from clinical trials examining the preventive effects of lipid-altering therapy in MS patients are needed to better define potential benefits and optimal treatment in this population...
  52. ncbi request reprint Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial)
    Prakash C Deedwania
    Veterans Affairs Central California Health Care System, University of California San Francisco, Fresno, California, USA
    Am J Cardiol 99:1538-43. 2007
    ....
  53. ncbi request reprint Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study
    Kiran K Khush
    Division of Cardiology, University of California, San Francisco School of Medicine, San Francisco, Calif, USA
    Circulation 115:576-83. 2007
    ..Statins reduce the rate of major cardiovascular events in high-risk patients, but their potential benefit as treatment for heart failure (HF) is less clear...
  54. ncbi request reprint ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients
    Raymond J Gibbons
    J Am Coll Cardiol 41:159-68. 2003
  55. ncbi request reprint Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF)
    Jalal K Ghali
    Cardiac Centers of Louisiana, Shreveport, LA 71103, USA
    Circulation 105:1585-91. 2002
    ..Underrepresentation of women in heart failure clinical trials has limited conclusions regarding the effect of various management strategies on survival in women with heart failure and decreased left ventricular ejection fraction (LVEF)...
  56. ncbi request reprint Consistency of the beneficial effect of metoprolol succinate extended release across a wide range dose of angiotensin-converting enzyme inhibitors and digitalis
    Jalal K Ghali
    Cardiac Centers of Louisiana, 2551 Greenwood Road, Suite 350, Shreveport, LA 71103, USA
    J Card Fail 10:452-9. 2004
    ....
  57. ncbi request reprint Efficacy, safety and tolerability of beta-adrenergic blockade with metoprolol CR/XL in elderly patients with heart failure
    Prakash C Deedwania
    University of California, San Francisco School of Medicine, San Francisco, CA, USA
    Eur Heart J 25:1300-9. 2004
    ..To study the efficacy and tolerability of beta-blockade in elderly patients with heart failure in the MERIT-HF study...
  58. ncbi request reprint Improving outcomes in post-acute myocardial infarction heart failure: incorporation of aldosterone blockade into combination therapy to optimize neurohormonal blockade
    Bertram Pitt
    University of Michigan Medical Center, William Beaumont Hospital, Ann Arbor, Michigan 48109, USA
    Am J Cardiol 97:26F-33F. 2006
    ..To achieve needed improvements in outcomes in this population, early and consistent initiation of these evidence-based, guideline-recommended therapies in all eligible patients is crucial...